ASH 2023 | Final analysis of CENTAURUS: daratumumab monotherapy for SMM
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, presents the results of the final analysis of the Phase II CENTAURUS study (NCT02316106), which assessed the efficacy and safety of daratumumab monotherapy in patients with intermediate- or high-risk smoldering multiple myeloma (SMM). Dr Landgren outlines the findings from the optional extension portion of the study, which elucidated that long-term use of daratumumab is safe and results in long-term progression control. An ongoing Phase III clinical trial, the AQUILA trial (NCT03301220), compares daratumumab monotherapy to active monitoring. Dr Landgren is hopeful that the results will lead to the approval of the first agent for SMM. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Honoraria: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on an entity’s Board of Directors or advisory committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on independent data monitoring committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex.
